Publications by authors named "Alessandro Alesina"
Article Synopsis
- Headache disorders like migraine and tension-type headaches are often underdiagnosed and undertreated, despite advancements in targeted medications; NSAIDs and analgesics are still the most commonly used treatments.
- A study conducted in 2022 at a tertiary headache center tracked 283 migraine patients, revealing that NSAID use decreased over three months while triptan use increased, indicating a shift in treatment strategies.
- Results showed that adding prophylactic therapies like topiramate or amitriptyline was linked to reduced NSAID intake and headache frequency, highlighting the need for tailored treatment plans in managing headaches effectively.
The new Calcitonin Gene-Related Peptide (CGRP)-targeted therapies have proven high efficacy and tolerability in episodic and chronic migraine. Eptinezumab is a humanized monoclonal antibody that selectively binds CGRP with high affinity. Eptinezumab was approved by the Food and Drug Administration on February 21st, 2020, for the preventive treatment of migraine in adults.
View Article and Find Full Text PDF